Speaker 1: Eleven three oh Global business news twenty four hours a
Speaker 1: day at Bloomberg dot com, the radio plus mobile LAPP
Speaker 1: and on your radio. This is a Bloomberg Business flag
Speaker 1: from Bloomberg World Headquarters. I'm Charlie Pellett. Stocks are advancing
Speaker 1: the SMP five hundred index within one percent of its record.
Speaker 1: Rallies and energy producers and airlines offsetting slumping healthcare shares.
Speaker 1: Right now, the SMP at seventeen the record on the
Speaker 1: SMP twenty one thirty reached last May. Right now, the
Speaker 1: SMP of four tenths of one percent to Dow also
Speaker 1: hired by four tenths of one percent, up seventy points
Speaker 1: to seventeen thousand, nine hundred ninety has stand up for
Speaker 1: a gain of point one percent. Ten You're up eight
Speaker 1: thirty seconds yield one point seven oh percent. Gold unchanged
Speaker 1: at twelve forty seven fifty crude trading above fifty dollars
Speaker 1: of barrel fifty forty two. Right now on West Texas
Speaker 1: Intermediate it is up by one and a half percent.
Speaker 1: I'm Charlie Pelleton. That's a bloom Bred business flash. You're
Speaker 1: listening to taking stock with on Bluebird Radio. Were are
Speaker 1: broadcasting live at Pershing's Inside Twenties sixteen conference at the
Speaker 1: Higher Regency in Orlando of Florida. And you know, planning
Speaker 1: for retirement means more than just having a personal plan
Speaker 1: to assure that you have enough money to enjoy your
Speaker 1: older age. It's also about having a health plan and
Speaker 1: being healthy in order to enjoy it. Here to tell
Speaker 1: us more is Dr Annette Khalid, Cancer Division Head and
Speaker 1: Associate Professor at the Burnett School of Biomedical Sciences, University
Speaker 1: of Central Florida College of Medicine. Dr Khaleen, thank you
Speaker 1: very much for being here. Now. I know that you
Speaker 1: spoke on the panel having to do with developing the
Speaker 1: next generation of treatments for cancer. I wonder if you
Speaker 1: could just speak a little bit about why this is
Speaker 1: such a crucial issue for all of the attendees here
Speaker 1: at this Pershing conference. So we're really at a or
Speaker 1: front right now and cancer research where we're making discoveries
Speaker 1: that are going to advanced cures for patients. But we've
Speaker 1: discovered that in order to personalize cure for a specific
Speaker 1: patients tumor, we had a lot more treatments that we
Speaker 1: have currently available. In fact, only about maybe two to
Speaker 1: three percent of patients actually have a type of tumor
Speaker 1: that can be treated with currently available drugs. We need
Speaker 1: a lot more drugs in the marketplace, and that's what
Speaker 1: labs like mine are doing, is we're discovering new drugs
Speaker 1: and trying to move them forward to commercialize them and
Speaker 1: get them into patients. That is stunning though, to say
Speaker 1: such a small amount of tumors are really only truly
Speaker 1: treatable with the current the current drugs, the current protocols
Speaker 1: you are on in the midst of something that's very important,
Speaker 1: because to cure cancer seems like the big thing is
Speaker 1: to figure out how it works and and get in
Speaker 1: the middle of that process so the cancer cannot develop, right,
Speaker 1: So talk to us about c T twenty P. It's
Speaker 1: a molecule that gets in the way of something called
Speaker 1: a chaperone in which is a key part of a
Speaker 1: tumor growing and developing and ultimately killing someone if you
Speaker 1: can't stop it. So you can, you've defined our platform
Speaker 1: very well. We actually discovered a therapeutic that is a
Speaker 1: small peptide that's really made of amino acids that are
Speaker 1: part of your bodies, you know, normal cells, and this
Speaker 1: peptide actually goes to cancer cells and specifically kills them.
Speaker 1: And the way it does it is because it interferes
Speaker 1: with very large machinery. It's also found in cells. It's
Speaker 1: called the chaperonein, and what chaperones do is they basically
Speaker 1: fold proteins in their final shapes so they can function.
Speaker 1: You know, d NA makes rna, RNA makes protein, but
Speaker 1: proteins don't stop. Their proteins have to have an activity,
Speaker 1: but they have to have the right shape to be
Speaker 1: able to have their activities. And that's what chaperoneins do.
Speaker 1: They actually make proteins reach the right shape so they
Speaker 1: can function and do their jobs. So cancer cells need
Speaker 1: a lot of proteins and they need a lot of
Speaker 1: proteins in the right shape. And so our pep tide
Speaker 1: blocks the shaperone and specifically in cancer cells and thereby
Speaker 1: reducing the number of proteins that confunction and cancer cells
Speaker 1: and cancer cells will then die. Dr Khalid maybe explain
Speaker 1: the kind of cancer that we're talking about here, because
Speaker 1: I understand that if you have cancer or tumor in
Speaker 1: one part of your body and then it metastasized, it
Speaker 1: shifts to other parts of your body. Now we're getting
Speaker 1: into an area where you can imagine people need a
Speaker 1: lot of help to just correct correct. So so usually
Speaker 1: the tumors localized or it's a primary tumor, a lot
Speaker 1: of treatments might be able to you know, surgeries or
Speaker 1: even you know, toxic compounds, chemotherapeutics, radiation can really deal
Speaker 1: with the localized tumors. It's when these tumors, as you mentioned,
Speaker 1: leave that primary location when they spread. They spread and
Speaker 1: they moved to the brain, when they moved to the
Speaker 1: lungs or the bones areas, they're really hard to treat
Speaker 1: and really hard to find, and so it's a challenge
Speaker 1: to find the treatments drugs that will actually help these
Speaker 1: patients eliminate the spread. And what we do with our
Speaker 1: treatment is actually target those cells specifically, we're targeting these
Speaker 1: cells that rove around and preventing them from basically moving.
Speaker 1: A lot of your work right now focusing on breast cancer.
Speaker 1: Correct We're using breast cancer is our model because it
Speaker 1: really affects so many women and it's really a challenge
Speaker 1: because when it metaticizes, there's very little choices out there.
Speaker 1: What about raising money to do exactly exactly so that's
Speaker 1: that's the challenge that we have. So you know where
Speaker 1: our ideas are very vulnerable because we don't have funding
Speaker 1: to see them through. And this is where we need funds.
Speaker 1: We need organizations like the Breast Cancer Research Foundation that
Speaker 1: funds studies like mine to be able to develop these
Speaker 1: ideas that we have into something that can be turned
Speaker 1: into a cancer drug for patients. Tell us a bit
Speaker 1: about and I'm sure one of the reasons is that
Speaker 1: you need money. And let's just underscore this that Dr
Speaker 1: Nekhalid is that the Burnett's School of Biomedical Sciences. And again,
Speaker 1: if you want to send some money or help our
Speaker 1: research co right ahead, yes, please, yes, because we're what
Speaker 1: we're doing is not only helping cancer, you know, survivors,
Speaker 1: preventing cancer, um menistetic cancer is not just breast cancer.
Speaker 1: There's so many cancers that you know, prostate, long liver,
Speaker 1: all these ministhetic sites. What we do can help those
Speaker 1: cancers as well. I just said that one the reason
Speaker 1: it's probably costly. You're using you know, you're harnessing nanotechnology
Speaker 1: for example. Tell us about some of the tools that
Speaker 1: are that you're developing and using to do this groundbreaking
Speaker 1: cancer search and discovery. Correct. So as we have a
Speaker 1: drug and we have a target, we have to get
Speaker 1: our drug to that target. And that's where now technology
Speaker 1: comes in. We can use these small nanoparticles and they're
Speaker 1: actually made of a polyester polymer. It's biodegradable, and we
Speaker 1: can load up these little nanoparticles with our PEP tide
Speaker 1: injected into you know, a patient, and have those nanta
Speaker 1: particles find the tumors and deliver our pep tide to
Speaker 1: those tumors. I wonder if you can describe also the
Speaker 1: idea of finding the right doctor or the right treatment.
Speaker 1: How does a patient go about doing this? Because it
Speaker 1: seems as though you could go online, but you could
Speaker 1: also end up in a place that is not necessarily
Speaker 1: going to give you stuff that's useful. You've actually hit
Speaker 1: a real problem in the field because you can have
Speaker 1: a lot of clinical trials and academic centers, but there
Speaker 1: are very few academic centers are accessible to all the patients.
Speaker 1: If you live in you know, a major city, find
Speaker 1: But what if you don't, how do you find these
Speaker 1: these treatments, these clinics. Your own doctor is still the
Speaker 1: best place to start with. But you know, we have
Speaker 1: to fix that. We have to make these clinical trials
Speaker 1: and these things in a way that's accessible to patients,
Speaker 1: not just you know, those patients that happen to live
Speaker 1: in an academic area. I'm still forging of those little
Speaker 1: polyous and your polymers who are grabbing the peptides and
Speaker 1: moving them around. It just it's just it's so it's
Speaker 1: fascinating U as far as very top down, we're in
Speaker 1: election year. If you were suddenly the czar of of
Speaker 1: on BAT team finding a cure for cancer, what would
Speaker 1: you say about the big system we have in place
Speaker 1: that needs to be changed. It needs to move forward.
Speaker 1: You're obviously mentioning money. Well, key is money. So first
Speaker 1: we need to put more money into these ideas. There
Speaker 1: there are thousands and thousands and thousands of scientists working
Speaker 1: on cures. We need money to move forward so we
Speaker 1: can develop our cures into break twos that can be
Speaker 1: developed in technologies. But more importantly, once we've got the
Speaker 1: technology in hand, we need to facilitate the process of
Speaker 1: getting through you know, intellectual property. The patent process takes
Speaker 1: way too long. I mean, waiting around for five years
Speaker 1: to get a patent issue it so you can commercialize
Speaker 1: your technology. That's way too much time to waste. We
Speaker 1: need to work with FDA to get things to happen faster,
Speaker 1: so we're not spending you know, eight to ten years
Speaker 1: waiting through all the clinical trials and everything to get
Speaker 1: to that point. So there's a lot of things that
Speaker 1: have to work handaha with government, with regulatory agencies to
Speaker 1: make things happen for the scientists who are developing new technologies.
Speaker 1: These new technologies primarily being developed in the United States,
Speaker 1: now all over the world. The United States is definitely
Speaker 1: a leader. You know, over fifty of our universities are
Speaker 1: working on basic science research that will lead to new
Speaker 1: discoveries education. You've been on this road for some time obviously,
Speaker 1: so much hard work to get to the level where
Speaker 1: you are. If you're if you're advising some young person
Speaker 1: about going into this field as a doctor, a scientist,
Speaker 1: someone who is working on the technology or even selling,
Speaker 1: I mean, what what advice would you give them at
Speaker 1: this point? Is this a growing field? This is a
Speaker 1: tough field. It's a tough field. But you follow your heart.
Speaker 1: That's what I tell everybody. You love what you do.
Speaker 1: You have to absolutely have a passion for what you
Speaker 1: do and if you have have that, you'll be successful.
Speaker 1: So I trained students in my lab, and I've got
Speaker 1: students who work in by a technology technology transfer who
Speaker 1: are doing academic like I'm doing myself. So I've trained
Speaker 1: students who do all sorts of different things with their degrees.
Speaker 1: Just follow your passion, follow your hearts, what I tell them.
Speaker 1: We are in Florida, so I do want to ask
Speaker 1: you a little bit about melanoma and carcinoma. You've got
Speaker 1: to because this is, you know, it seems like something
Speaker 1: that only you avoid when you're you know, young and
Speaker 1: and and healthy, but it can come back and hurt
Speaker 1: you later later on. What kind of advances or what
Speaker 1: kind of treatments are are currently being worked on. Some
Speaker 1: great immunotherapy is coming out there, teaching your body to
Speaker 1: you know, function and kill the cancers themselves, enabling your
Speaker 1: your body to defend yourself. And of course where your
Speaker 1: sun screen and where your hat if you're in Florida.
Speaker 1: It sounds like a good idea. I want to thank
Speaker 1: you very much for spending time with us. Dr Annette
Speaker 1: Khali is the ahead of the Cancer Division and Associate
Speaker 1: professor the Burnett School of Biomedical Sciences at the University
Speaker 1: of Central Florida College of Medicine. You're listening to Taking
Speaker 1: Stockh'm PIM Fox my co host Kathleen Hayes. We are
Speaker 1: broadcasting live at Persian's Inside Conference at the Hyatt Agency
Speaker 1: in Orlando. This year marks eighteen years of insight, eighteen
Speaker 1: years committed to the success of advisors. Were here with
Speaker 1: over two thousand financial professionals from all over the globe.
Speaker 1: And you're listening to the Bloomberg Radio